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The objective of the present paper was to determine the inﬂuence of fructooligosaccharide (FOS) on the pharmacokinetics of
isoﬂavones in healthy postmenopausal women. The study was a ﬁxed-sequence, two-phase, crossover study. Twelve subjects
received a single oral dose of 300mL of a soy beverage. Blood samples were collected before the dose and at 0.5, 1, 2, 4, 6, 8, 10, 12,
24,and 32hafter the administrationof the soybeverage. Aftera washout periodof at least 1week, subjects were assigned toreceive
oral doses of FOS, 5g each time, twice a day (after breakfast and dinner) for 14 days, followed by a single oral dose of the same
soy beverage on the next day. Blood samples were then collected at the same time points mentioned previously. Plasma isoﬂavone
concentrations were determined by HPLC. Continuous oral administrations of FOS followed by a single oral administration of
soy beverage caused signiﬁcant increases in Cmax,A U C 0–32, and AUC0–∞ of genistein and AUC0–32 of daidzein, comparing to those
obtained following a single oral dose of soy beverage alone. Other pharmacokinetic parameters (Tmax and t1/2 of both aglycones
and AUC0–∞ of daidzein) between both regimens were not signiﬁcantly diﬀerent.
1.Introduction
Decreased estrogen level demonstrated in postmenopausal
women commonly relates to a variety of disorders, for
example, hot ﬂushes, osteoporosis, depression, increased
body weight, and so forth. As a therapeutic goal, hormone
replacement therapy (HRT) has been used for decades as
the “gold standard” to treat estrogen deﬁciency symptoms
[1]. Estrogen therapy has been demonstrated to beneﬁt post-
menopausal women mostly through the relief of vasomotor
symptoms as well as for the prevention and treatment of
osteoporosis [2]. However, estrogen therapy has been shown
to increase the risk of breast cancer, uterine and endometrial
cancer, as well as menstrual bleeding [3]. Although the
incidence of endometrial cancer can be avoided by using
estrogen plus progestin [4], this combination increases the
risks of stroke, pulmonary embolism, and invasive breast
cancer [5]. Therefore, both postmenopausal women and
physicians remain concerned about the adverse eﬀects of
estrogen and are looking for natural products that possess
beneﬁcial eﬀects similar to estrogen but have more favor-
able safety proﬁles. Indeed, phytoestrogens oﬀer attractive
options because they have been demonstrated to decrease
the risk of endometrial and breast cancer, avoid the need
for progestin, have fewer adverse reactions, and still provide
health beneﬁts [6].
Isoﬂavones represent the most common group of phy-
toestrogens, and soybeans are the most common source
of isoﬂavones in human food. Isoﬂavones are structurally
similar to estrogen but possess weaker hormonal eﬀects.
They bind weakly to the estrogen receptor alpha (ERα)o f
the reproductive organs such as the uterus, ovaries, and
breast, but bind more strongly to the estrogen receptor beta
(ERβ) found in the brain, arteries and bone [7], and have2 Evidence-Based Complementary and Alternative Medicine
been associated with beneﬁcial eﬀects in humans, such as
the relief of hot ﬂushes, and the prevention of osteoporosis,
cardiovascular diseases, and cancers [8].
The unconjugated aglycones (daidzein, genistein, and
glycitein) are contained predominantly in fermented soy-
based products (such as tempeh and miso) due to micro-
organism-induced hydrolysis of their respective glycoside
conjugates into aglycones, whereas most nonfermented soy-
based products (such as tofu, soymilk, soy ﬂour, etc.) largely
contain mixtures of their malonyl-, acetyl-, and nonconju-
gated β-glycosides [9]. All glycosides are biologically inactive
andpoorlyabsorbedfromtheintestinaltractbecauseoftheir
hydrophilicity and larger molecular size [10]. Hydrolysis
of the glycosidic bond using β-glucosidases is therefore
necessary to release the biologically active aglycones which
are rapidly absorbed across the intestinal wall [7, 10,
11]. The β-glucosidases involved in this step are found
in the small intestinal brush border (lactase phloridzin
hydrolase ([LPH])) [12] and within enterocytes (cytosolic
β-glucosidases) [13]. Nonetheless, isoﬂavone glycosides that
are not absorbed in the small intestine will pass through
to the colon, where bacterial β-glycosidases can hydrolyze
them and additional absorption can be exerted [10, 14–16].
Several groups of colonic bacteria including Lactobacillus
spp., Bacteroides spp., and Biﬁdobacterium spp. possess β-
glucosidase activity and have been demonstrated to be very
eﬀective deglycosylators [14].
Prebiotics such as fructooligosaccharides (FOSs) are
poorly digested in the human small intestine but are fer-
mented in the colon by the resident microﬂora [17]. FOS is
also found to be fermented in vitro only by a speciﬁc range
of microﬂora that include most species of biﬁdobacteria
[18, 19]. The oral administration of FOS for 7 days has been
reported to signiﬁcantly increase fecal biﬁdobacteria counts
in healthy volunteers [20]. As aforementioned, this increased
number of colonic biﬁdobacteria theoretically leads to an
enhancement of bacterial β-glucosidase activity in the colon.
It is possible that supplementation with FOS could increase
the isoﬂavone absorption through enhancement of bacterial
β-glucosidase activity [15]. Uehara et al. have shown that
plasma and urine levels of genistein and daidzein are higher
in the rat fed with FOS than the control rat [21]. In addition,
an additive eﬀect of dietary isoﬂavones and FOS has been
demonstratedonthebonemineraldensityinovariectomized
mice [22]. However, the study of FOS on plasma isoﬂavone
concentrations in human is still lacking. Therefore, the
purpose of this study was to determine the inﬂuence of
FOS on the pharmacokinetics of isoﬂavones in healthy, Thai
postmenopausal women.
2.MaterialsandMethods
2.1. Study Design. The study was a ﬁxed-sequence, two-
phase study with a washout period of at least one week. The
study was approved by the Human Research Ethics Commit-
tee of the Faculty of Medicine, Chiang Mai University, and
complied with the Helsinki Declaration.
2.2. Subjects. A total of 12 Thai postmenopausal women,
age >45y, postmenopausal status >1y (since the last sponta-
neous menstrual bleeding), and serum follicle-stimulating
hormone concentration >30IU/L, were enrolled in this
study. The body mass index (BMI) of subjects was within
18–25kg/m2. All had to be in good health based on med-
ical history, physical examination, and routine blood tests
including complete blood count, blood urea nitrogen, cre-
atinine, and liver function tests. Exclusion criteria were
history of malignancy, chronic renal, liver, cardiovascular,
pulmonary or breast disease, a history of substance abuse
or addiction, recent cigarette smoking, regular consumption
of >2 alcoholic drinks/d, regular use of over-the-counter or
prescription medication (>1 dose/wk), use of antibiotics and
laxatives within the previous 4weeks, and intake of nutri-
tional supplements (containing vitamins, minerals, ﬁbers,
FOS, isoﬂavones, other prebiotics or probiotics) within the
previous 2weeks.
2.3. Soy Preparation and FOS. The soy preparation used in
this study was a commercial instant soy beverage D in 1
(manufactured by T.C. Pharmaceutical, Co., Ltd., Thailand),
prepared by mixing 1 sachet (36g) of soy powder with
300mLofhotwater.Themeanisoﬂavonecontentsofdaidzin
and genistin were 11.24 ± 2.84 and 23.82 ± 1.03mg/serving,
respectively. The amounts of daidzein and genistein were
negligible. FOS used in this study was Meioligo granule
2.5g/sachets, manufactured by Meiji Seika Kaisha, Ltd.,
Tokyo, Japan.
2.4. Dosage and Drug Administration. Subjects were admit-
ted to the Clinical Pharmacology Unit of the Faculty
of Medicine, Chiang Mai University, at 6:30AM after an
overnight fast of at least 8h. Each received a single oral dose
of 300mL soy beverage (D0) (single ISO phase). The subjects
were instructed to remain upright and fast for 2h after
administration of the soy beverage. Water and lunch were
served at 2h and 6h after dosing, respectively. Blood samples
were collected at speciﬁc time points (see the following).
Following blood sample collection at 12h after the soy dose,
thesubjectsweredischarged fromtheClinical Pharmacology
Unit and were asked to come back again on the next day
for blood sample collections at 24h and 32h after the initial
dose. After a washout period of at least 1week, subjects
received oral doses of FOS, 5g each time, twice a day (after
breakfast and dinner) for 14 days (D−14–D−1), followed by a
single oral dose of 300mL soy beverage on the next day (D0)
(continuous FOS/single ISO phase). Administrations of soy
beverageandbloodsamplecollectionswereperformedinthe
same manner as in the former phase. An identical food and
beverage containing no isoﬂavones were served during both
phases. Subjects were required to refrain from drinking some
beverages (e.g., soy milk, alcohol and caﬀeine containing
beverages, etc.).
2.5. Blood Samples Collection. Venous blood samples (7mL
each) for determination of plasma isoﬂavones were collected
b e f o r et h ed o s e ,a n dt h e na t0 . 5 ,1 ,2 ,4 ,6 ,8 ,1 0 ,1 2 ,2 4 ,
and 32h after administration of the soy beverage. Samples
were obtained from the forearm by venipuncture throughEvidence-Based Complementary and Alternative Medicine 3
an indwelling intravenous catheter and collected in a hepar-
inized vacutainer. The blood collecting tubes were centri-
fuged at 1,200rpm for 15min and the plasma was separated
and frozen at −80◦C for later analysis.
2.6. Determination of Plasma Concentrations of Isoﬂavones
2.6.1. Sample Preparation. T h es a m p l ep r e p a r a t i o na n dd e -
termination of isoﬂavone concentrations in plasma were
modiﬁed from the method described by Teekachunhatean et
al. [23]. An aliquot of 250μL of plasma was transferred to
a 1.5mL plastic vial and treated with 0.15mL of a mixture
of β-glucuronidase/sulfatase from Helix pomatia (Sigma G-
0876) to hydrolyze glucuronide and sulfate conjugates of
genistein and daidzein. The enzyme mixture was made up
freshly and contained 0.1g ascorbic acid in 10mL of 0.1M
sodium acetate buﬀer, 0.01g ethylenediaminetetraacetic acid
(EDTA), and 250μLo fHelix pomatia. The tubes containing
the enzyme mixture were capped and heated overnight in a
water bath (15–18h, 37◦C) and then were allowed to cool to
room temperature.
After enzymatic hydrolysis, plasma samples were spiked
with10μL of internal standard (IS, 50,000ng/mL ﬂuorescein
in 80% methanol) and then deproteinated by mixing the
plasmasamplewith1,000μLof1%aceticacidinacetonitrile,
vortex mixing for 30sec, and centrifuged at 14,000rpm
for 10min, respectively. An aliquot of the supernatant was
removed and evaporated to vacuum dried for 3h at 60◦C.
The residue was dissolved in 50μL of mobile phase B, and
5μL of the sample was injected into the HPLC system. Chro-
matogram of isoﬂavone-free plasma is shown in Figure 1(a),
whereas chromatogram of plasma containing 2,400ng/mL
of daidzein and genistein as well as 10,000ng/mL of IS is
presented in Figure 1(b).
2.6.2. High-Performance Liquid Chromatography (HPLC)
Conditions. The assay of isoﬂavones was modiﬁed from
the HPLC method and conditions previously described
by Teekachunhatean et al. [23]. The samples were eluted
on a C18 column (Inertsil, 150mm × 4.6I.D., 5μm, GL
Science, Tokyo, Japan) with a C18 guard column (Inertsil
ODS-3, 10mm × 4.0I.D., 5μm, GL Science, Tokyo, Japan).
The chromatography condition consisted of two mobile
phases. Mobile phase A was 55mM ammonium acetate in
deionized water/acetonitrile/methanol (250:45:45, v/v/v).
Mobile phase B was 55mM ammonium acetate in deionized
water/acetonitrile/methanol (250:255:220, v/v/v). Both
mobile phases contained 29μL of perchloric acid and
250μL of 1.44mM sodium dodecyl sulfate. Separation was
performed at 25◦C. A gradient elution of 90% A with
10% B for 3.5min, 50% A with 50% B at 3.5–6.5min,
30% A with 70% B at 6.5–9.2, and 5% A with 95% B at
9.2–12.8min was scheduled. The ﬂow rate of mobile was
maintained at 1mL/min, and the analyses were detected
by UV absorption at 259nm. The isoﬂavone contents of
samples were determined by using a calibration curve of
peak height ratios of isoﬂavones and IS versus respective
isoﬂavone concentrations (37.5, 75, 150, 300, 600, 1,200, and
2,400ng/mL) with the use of linear regression. The linear
regression analysis of peak height ratios of isoﬂavones versus
isoﬂavone concentrations consistently yielded coeﬃcients of
determinant (r2) of 0.997 or better.
For intraday validation, 5 samples from each of 3 quality
control (QC) samples (112.5, 1,100, 2,200ng/mL) were eval-
uated with a single calibration curve. For interday validation,
5s e t so ft h e3d i ﬀerent concentrations of QC samples (112.5,
1,100, 2,200ng/mL) were studied on 5 independent days
with concurrent 5 standard calibration curves. The precision
was reported as the percentage of coeﬃcient of variation (%
CV) which was calculated as follows:
%C V=
SD
X
×100, (1)
where SD was standard deviation and X was mean value of
isoﬂavone concentration in plasma.
The deviation was expressed as the percentage of inaccu-
racy calculated by the following equation:
%D e v i a t i o n
=

Measured concentration −Spiked concentration

Spiked concentration
×100.
(2)
For the determination of daidzein concentrations in
plasma, the % CV of intraday precision for the 3 QC
samples was 2.65%, 1.36%, and 1.29%, respectively, whereas
that of interday precision was 6.04%, 1.10%, and 3.05%,
respectively. The % deviation of intraday assay for the 3
QCsampleswas −5.49%, −1.32%,and −1.07%,respectively,
whereas that of interday precision was −2.40%, 0.61%, and
3.23%, respectively.
For the determination of genistein concentrations in
plasma, % CV of intraday precision for the 3 QC samples
was 4.48%, 1.71%, and 1.30%, respectively, whereas %
CV of interday precision was 2.57%, 1.83%, and 3.34%,
respectively. The % deviation of intraday assay for the 3 QC
samples was 4.48%, 1.71%, and 1.30%, respectively, whereas
those of interday precision was 2.52%, −0.40%, and 2.46%,
respectively.
The mean recovery of daidzein and genistein from the
determination procedure was 94.69 ± 3.10% and 92.54 ±
2.97%, respectively.
2.7. Data Analysis and Statistical Methods
2.7.1.PharmacokineticParameters. Maximalplasmaconcen-
tration (C max, ng/mL) and time to reach peak concentration
(Tmax, h) were obtained directly by visual inspection of
each subject’s plasma concentration-time proﬁle. The area
under the plasma concentration-time curve from time 0–
32h and 0–∞ h( A U C 0–32 and AUC0–∞,n g ·h/mL) as well
as half-life (t1/2, h) was determined by noncompartmental
analysis. The slope of the terminal log-linear portion of the
concentration-time proﬁle was determined by least-squares4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: (a) Chromatogram of isoﬂavone-free plasma. (b) Chromatogram of plasma sample containing 2,400 ng/mL of daidzein (k =
11.437 min) and genistein (k = 13.514 min) as well as 10,000ng/mL of IS (k = 9.772 min).
regression analysis and was used as the elimination rate
constant (ke). The elimination half-life was calculated as
0.693/ke. The AUC from time zero to the last quantiﬁable
point (AUC0–32) was calculated using the trapezoidal rule.
Extrapolated AUC from time t to inﬁnity (AUCt–∞)w a s
determinedasCt/ke.T otalA UC 0–∞ wasthesumofAUC0–32 +
AUC32–∞.The calculation was performed by using the TopFit
software version 2.0 for PC.Evidence-Based Complementary and Alternative Medicine 5
Table 1: The demographic characteristics of 12 subjects enrolled in
this study.
Subject Age Weight Height BMI FSH
No. (y) (kg) (m) (kg/m2) (mIU/mL)
1 56 57.00 1.52 24.67 41.56
2 58 48.50 1.47 22.44 73.46
3 64 59.00 1.60 23.05 61.71
4 62 55.00 1.51 24.12 60.78
5 50 58.50 1.65 21.49 90.77
6 55 53.00 1.52 22.44 86.68
7 54 59.00 1.54 24.88 79.67
8 55 56.00 1.53 23.92 90.55
9 53 48.50 1.52 20.99 125.84
10 46 54.00 1.55 22.48 30.53
11 67 42.00 1.46 19.70 80.14
12 54 51.00 1.47 23.60 57.87
Mean 56.17 53.46 1.53 22.81 73.30
SD 5.87 5.18 0.05 1.55 25.22
2.7.2. Statistical Analysis. The pharmacokinetic parameters
were presented as mean ± SD. The diﬀerences in the mean
values of pharmacokinetic parameters obtained from both
phases were compared by using the Wilcoxon’s signed-rank
test. A P value <0.05 was considered signiﬁcant.
3. Results
The demographic characteristics of 12 female subjects
enrolled in the study are shown in Table 1.A l ls u b j e c t sc o m -
pleted the study.
The mean plasma concentration-time curves of daidzein
and genistein from 12 subjects receiving single ISO versus
continuous FOS/single ISO are shown in Figures 2 and 3,
respectively. The plasma concentration-time proﬁles of daid-
zein and genistein in both phases showed wide intraindivid-
ual and interindividual variation but were typically biphasic
ineveryindividual regardlessoftheregimens taken(datanot
shown).Theﬁrstandsecondpeakconcentrationsofdaidzein
andgenistein obtained from both phases wereapproximately
reached at 2–4h and 6–8h, respectively. The second peak
concentrations of both isoﬂavones were always higher than
the ﬁrst peak.
The pharmacokinetic parameters of daidzein and genis-
tein (Cmax,A U C 0–32,A U C 0−∞, Tmax, t1/2) after oral admin-
istration of soy preparation in both phases were determined
andareshowninTable 2.Ofallpharmacokineticparameters,
it was shown that Cmax,A U C 0–32,a n dA U C 0–∞ of genistein
as well as AUC0–32 of daidzein obtained from continuous
FOS/single ISO phase were signiﬁcantly higher than those
of single ISO phase. For genistein, the mean Cmax and AUC
obtained from continuous FOS/single ISO phase were about
40% and 25%–30% and signiﬁcantly higher comparing to
those of “single ISO” phase. However, the mean AUC0−32 of
daidzein obtained from “continuous FOS/single ISO” phase
was only slightly (∼15%) but statistically higher than that
0
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Figure 2: Mean plasma daidzein concentration-time curves from
12 subjects receiving a single oral administration of soy beverage
(single ISO phase) and continuous oral administrations of FOS
followedbyasingleoraladministrationofsoybeverage(continuous
FOS/single ISO phase).
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Figure 3: Mean plasma genistein concentration-time curves from
12 subjects receiving a single oral administration of soy beverage
(single ISO phase) and continuous oral administrations of FOS
followedbyasingleoraladministrationofsoybeverage(continuous
FOS/single ISO phase).
of “single ISO” phase. It is worth noting that signiﬁcant
increases in AUC0−32 of both aglycones in “continuous
FOS/single ISO” phase were consistent with the higher
second peaks of the plasma concentration-time curves,
whereas the ﬁrst peaks obtained from both phases were
exactly the same.
Data from “continuous FOS/single ISO” phase revealed
that 4 out of 12 postmenopausal subjects demonstrated
only minimal increases in AUC0–32 (1%–10% increment)
of daidzein, but 7 out of 12 demonstrated remarkable
increases in AUC0–32 (>10% increment). Similarly, 3 out
of 12 demonstrated only minimal increases in AUC0–32
of genistein, and 8 out of 12 demonstrated remarkable
increasesinAUC0–32.Additionally,onesubjectdemonstrated
adecr easeinA UC 0–32 ofbothdaidzein(−33%)andgenistein
(−16%).6 Evidence-Based Complementary and Alternative Medicine
Table 2: Pharmacokinetic parameters of daidzein and genistein obtained from 12 subjects receiving a single oral administration of
soy beverage (single ISO phase) and continuous oral administrations of FOS following by a single oral administration of soy beverage
(continuous FOS/single ISO phase).
Pharmacokinetic parameters Daidzein Genistein
Single ISO Continuous FOS/single ISO Single ISO Continuous FOS/single ISO
Cmax (ng/mL) 363.33 ±116.67 412.90 ±100.61 347.01 ±143.42 489.65 ±187.15
∗
AUC0–32 (ng·h·mL) 2753.71 ±1227.64 3177.32 ±1474.55
∗ 4096.66 ±2050.96 5354.39 ±2650.16
∗
AUC0–∞ (ng·h·mL) 3399.35 ±1261.82 3741.85 ±1421.28 5075.62 ±2787.77 6321.17 ±3047.63
∗
Tmax (h) 6.67 ±1.78 6.67 ±1.78 6.00+ 1.91 6.67 ± 1.56
t1/2 (h) 4.65 ±2.46 5.27 ±2.50 9.61 ±4.45 10.01 ±4.17
Data represents mean ± SD. ∗P < 0.05 versus single ISO phase.
4. Discussion
This is the ﬁrst study to investigate the inﬂuence of FOS on
pharmacokinetics of isoﬂavones in healthy postmenopausal
women. Twelve subjects in this study were enrolled in accor-
dance to the number of subjects in the previous study
demonstrating that supplementation with prebiotic inulin
signiﬁcantly increases the extent of isoﬂavone absorption
[24].
Despite the mixtures of malonyl-, acetyl-, and β-gly-
coside conjugates of daidzein and genistein are the major
isoﬂavones found in most nonfermented soy-based products
[16], both malonyl- and acetyl-conjugates can readily be
hydrolyzed to their respective more heat-stable β-glycoside
conjugates during exposure to processing temperature [9].
Hence this is the reason why daidzein and genistein were
demonstrated to be the major forms of isoﬂavones in the
instant soy beverage used in this study. The soy preparation
containing the predominant isoﬂavone glycosides (daidzin
and genistin) rather than aglycone forms was chosen because
it has been hypothesized that FOS increases isoﬂavone
bioavailability via stimulation of gut microﬂora ability to
hydrolyze isoﬂavone glycosides to their respective more
readily absorbable aglycones. Additionally, soy beverage was
considered the formulation of choice rather than other
commercially available soy extract capsules because the β-
glycoside conjugates dissolved in soy beverage are ready to
be hydrolyzed and further absorbed without the necessity
of determining their disintegration and dissolution proﬁles,
whichareimportant confoundingfactorsduring absorption.
Although daidzin and genistin in the ingested soy bever-
age need to be hydrolyzed by the intestinal or gut microﬂora
β-glucosidases to release free aglycones prior to absorp-
tion, the absorbed aglycones are further predominantly
metabolized to their β-glucuronide conjugates, and to lesser
amounts also as sulfate conjugates, in the intestine and/or
liver [25]. Therefore, the glucuronide and sulfate conjugates
are the major metabolites of isoﬂavones found in systemic
circulation. Treating plasma samples with a mixture of
β-glucuronidase/sulfatase before determination of plasma
isoﬂavone concentrations in this study resulted in enzymatic
hydrolysis of glucuronide and sulfate conjugates to aglycones
(daidzein and genistein). Thus, plasma concentrations of
the respective aglycones were determined rather than their
glucuronide and sulfate conjugates [23].
The mean Tmax of daidzein (6.67 ± 1.78h) and genistein
(6.00 ± 1.91h) obtained from single ISO phase of this study
was quite shorter than that of 8–11h after ingestion of
isoﬂavone conjugates reported in other studies [26, 27].
This discrepancy might be as a result of such factors
as ethnic background, soy preparations used, intestinal
microﬂora, and dietary habits. However, the Tmax reported
here was comparable to that of our previous studies in Thai
postmenopausal women [23, 28]. Additionally, the mean t1/2
of daidzein and genistein was 4.65±2.46h and 9.61±4.45h,
respectively, which are in agreement with those of 3–9h for
daidzeinand8–11hforgenisteinaftertheintakeofsoyfoods
or pure isoﬂavone glycosides [29, 30].
In this study, a typical biphasic pattern appeared in
both phases for all individuals, as well as in mean plasma
concentrations-time curves of postmenopausal subjects.
This ﬁnding is consistent from those reported elsewhere
[26, 29, 31]. Plasma concentrations of isoﬂavones could
be detected as early as 30min, and the ﬁrst peak was
attained at approximately 2–4h after soy intake. It has been
reported that this early detection of plasma levels and the
presentation of the ﬁrst peak correspond to the hydrolysis
of β-glycoside conjugates and initial absorption of aglycones
readily occurring in the duodenum and proximal jejunum
[26, 29, 32, 33]. Additionally, the second peak attained at
6–8h corresponds to an ability of gut microﬂora to cleave
β-glycosides to their respective aglycones before the latter
can be absorbed mainly in the large intestine [10, 14–
16]. The large intestine is known to be the location where
resident microﬂora are present in the largest numbers and
consequently play the most crucial role for the uptake of
isoﬂavones [33]. The signiﬁcant delay of the second peak
after the radical reduction of the gut ﬂora, achieved by
mechanical bowel preparation in combination with oral
antibiotic treatment, emphasizes further evidence that this
peak corresponds to colonic bacterial β-glucosidase activity
[33].
In the “continuous FOS/single ISO” phase of this study,
the signiﬁcant increases in Cmax (of genistein) and AUC
(of both daidzein and genistein), compared to those of
“single ISO” phase, correlated to the higher second peaksEvidence-Based Complementary and Alternative Medicine 7
of the plasma concentration-time curves. These ﬁndings
suggestthatpretreatmentofFOSfor14da ysmighteﬃciently
lead to stimulation of microﬂora growth especially in the
colon,resultinginenhancementofmicroﬂoraβ-glucosidases
activity, and hence increased oral absorption of both agly-
cones. These are consistent with the previous study, which
demonstrated that oral administration of FOS signiﬁcantly
increases the absorption of both aglycones in rats, especially
during 6–48h after isoﬂavone intake [21]. Similarly, study
in healthy postmenopausal women has shown that plasma
concentrations of both aglycones are signiﬁcantly higher
after the oral consumption of isoﬂavones plus prebiotic
inulin for 21 days, compared to those of without inulin
[24].
The present investigation revealed that the majority of
study subjects demonstrated remarkable increases in AUC
(>10% increment) of both aglycones, whereas the minor-
ity (approximately 40% of participants) showed minimal
increases or even decrease in these parameters. This dis-
crepancy reﬂects the diﬀerent potential of FOS to stimulate
gut microﬂora growth, which might be due mainly to
variations in basal amount and type of resident microﬂora
responsible for isoﬂavone conversion, as well as their ability
to metabolize glycoside conjugates in the intestinal milieu
of diﬀerent individuals [34]. Although FOS seems likely
to stimulate a limited range of microorganisms, especially
biﬁdobacteria [18], it is speculated that the growth of
other bacterial species in some individuals might be simul-
taneously stimulated, leading to an increase in the bio-
transformation of isoﬂavones to metabolites other than
their respective aglycones; for example, daidzein can be
further metabolized to equol and O-desmethylangolensin,
and genistein to p-ethyl phenol [16]. Indeed, it appears
that more than one bacterial species could be involved
in the metabolic conversions of these aglycones [35]. On
the other hand, it is still uncertain whether an increased
amount of biﬁdobacteria under some speciﬁc circumstances
could further metabolize daidzein and genistein to other
constituents resulting in lower oral bioavailability of these
aglycones in some individuals. Therefore, the correlation
between changes in isoﬂavone bioavailability versus the
fecal bacterial counts (including biﬁdobacteria and others)
and/or β-glucosidase activity in the fecal contents after FOS
supplement should be further investigated, to clarify the
unansweredquestionofhowFOSaﬀectsthebacterialgrowth
especially in subjects whose isoﬂavone bioavailability cannot
be increased or even decreased.
Interestingly, present and previous studies have unan-
imously demonstrated that FOS or inulin remarkably
enhances the absorption of genistein, rather than daidzein
both in rats [21], and in human subjects [24]. Since the com-
bination of dietary FOS and isoﬂavones has been shown to
correlate with increased plasma equol levels in rats [36, 37],
and 30% of humans can metabolize daidzein to equol that is
detectableinsystemiccirculation[15],itishypothesized that
enhancement of the conversion of daidzein to equol (and/or
O-desmethylangolensin) from increased bacterial growth
following FOS supplement could explain why it is less likely
to increase the bioavailability of daidzein in comparison to
genistein. Nonetheless, the role of biﬁdobacteria involving
in the reductive pathway of daidzein toward equol is still
controversial. Although the formation of equol in soymilk
fermented with some strains of biﬁdobacteria has been
reported [38], 22 strains of biﬁdobacteria fail to transform
daidzein into equol under various experimental conditions
in vitro. These ﬁndings exclude any role of biﬁdobacteria in
the production of equol [39]. Thus, the determination of
plasmaconcentrationsofequolespeciallyinsubjectsdemon-
strating lesser enhancement of isoﬂavone bioavailability after
FOS supplement should be further studied. However, the
presentation of biologically active equol in plasma after FOS
supplement,ifany,mightbeabletoproducebeneﬁcialeﬀects
in postmenopausal women despite no signiﬁcant increase in
the bioavailability of daidzein, because equol possesses more
estrogenic activity than daidzein and binds more strongly to
the estrogen receptors [40]. It also has a longer half-life and
superior antioxidant activity [41, 42].
Since the second peak of both isoﬂavones was demon-
s t r a t e dt ob ea ta p p r o x i m a t e l y2 ha f t e rl u n c hi nm o s t
subjects enrolled in this study, this ﬁnding indicates that
the β-glucuronide and sulfate conjugates excreted via bile
during lunch time might be further deconjugated by the
gut microﬂora and undergo enterohepatic recirculation as
s u g g e s t e db yp r e v i o u ss t u d i e s[ 43, 44]. This additional
absorption of isoﬂavones into systemic circulation possibly
accounts for the second surge of plasma concentrations [29].
Whether stimulation of bacterial growth after FOS admin-
istration contributes to enhancement of gut microﬂora β-
glucuronidase activity, and hence increase in enterohepatic
recirculation during the second peak, is still equivocal and
warrants further investigation.
In the present study, continuous administration of
FOS could increase AUC of daidzein and genistein by
approximately 15% and 30%, respectively, whereas other
studies showed that doubling the oral dose of soy nuts
from 20 to 40g yields increments of AUC by approximately
80% and 40%, respectively [30]. Therefore, increased oral
ingestion of isoﬂavones or soy foods seems to be a simple
but more eﬀective and less costly means to enhance oral
isoﬂavone bioavailability in comparison to coadministration
of ﬁxed-dose isoﬂavones plus FOS. Nonetheless, FOS has
been found to increase intestinal absorption of calcium in
rats [45] and humans [46, 47], presumably by stimulating
growth of resident microﬂorasuch as biﬁdobacteria. In addi-
tion, soy foods combined with a prebiotic signiﬁcantly
improve the lipid proﬁles in hyperlipidemic adults, possibly
via an increase in colonic microbial biotransformation of
isoﬂavones and/or speciﬁc short-chain fatty acids [48].
Therefore, coadministration of isoﬂavones plus FOS might
play some advantageous role in certain circumstances, such
as in postmenopausal women with coexisting osteoporosis
and/or dyslipidemia.
The major limitations of this study were listed as follows.
Firstly, since the carry-over eﬀect of FOS on enhancement of
bacterial growth especially in vivo is not well understood, the
study was therefore designed as ﬁxed-sequence rather than a
randomized-sequence cross-over study in order to avoid any
possible residual eﬀect of FOS. Secondly, a further limitation8 Evidence-Based Complementary and Alternative Medicine
is the lack of quantiﬁcation of fecal bacterial counts, β-
glucosidase activity in the fecal content, and plasma levels of
equol.
5. Conclusion
Continuous oral administrations of FOS followed by a sin-
gle oral administration of soy beverage caused signiﬁcant
increases in Cmax,A U C 0–32,a n dA U C 0–∞ of genistein and
AUC0–32 of daidzein, compared to those obtained following
a single oral dose of soy beverage alone.
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